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AbstrACt 
Introduction Pharmacotherapy plays an important role 
in the treatment of major depression. At the initiation of 
antidepressant treatment, both improvement of symptoms 
in the short term and relapse prevention in the long term 
should be taken into account. However, there is insufficient 
evidence regarding the efficacy and the acceptability of 
continuation/maintenance treatments and the relative 
efficacy/acceptability of antidepressants.
Objective We will conduct a pairwise meta-analysis and 
a network meta-analysis (NMA) to examine the relative 
efficacy, tolerability and acceptability of antidepressants in 
the long-term treatment of major depression.
Methods and analysis We will include double-blind 
randomised controlled trials comparing any of the 
following antidepressants, which we included in our 
previous NMA of the acute treatment for major depression, 
with placebo or with another active drug for long-term 
treatment of major depression: agomelatine, amitriptyline, 
bupropion, citalopram, clomipramine, desvenlafaxine, 
duloxetine, escitalopram, fluoxetine, fluvoxamine, 
levomilnacipran, milnacipran, mirtazapine, nefazodone, 
paroxetine, reboxetine, sertraline, trazodone, venlafaxine, 
vilazodone and vortioxetine. Our primary outcomes will 
be sustained response and all-cause dropouts. We will 
include four types of designs that are used to investigate 
long-term treatment. We will conduct two main analyses. 
First, we will conduct a pairwise meta-analysis comparing 
all antidepressants versus placebo to investigate whether 
continuing antidepressants after achieving a positive 
response in the acute-phase treatment is beneficial and/
or safe. Second, we will conduct an NMA to examine the 
comparative efficacy and acceptability of the drugs. We 
will use a novel approach that will combine the results 
of acute-phase treatment NMA with long-term treatment 
studies to include all related designs in the NMA. We will 
ensure the validity of combining different designs and our 
new approach by checking the distribution of important 
effect modifiers and consistency of network.
Ethics and dissemination This study did not require 
ethical approval. We will disseminate our findings by 
publishing results in a peer-reviewed journal.
PrOsPErO registration number CRD42018114561; 
Pre-results.
IntrOduCtIOn
Depression is estimated to affect over 
300 million people across the world and 
contributes 7.5% of all years lived with 
disability in the overall global burden of 
disease.1 It runs a chronic-recurrent course 
as 30%–40% of cases experience recurrent 
episodes within a year.2 Studies show that 
the years of life lived with disability due to 
depressive disorders increased by 37.5% 
between 1990 and 2010. Two-thirds of this 
increase comes from population growth, 
and one-third came from population ageing 
without a change in age-specific prevalence, 
strengths and limitations of this study
 ► Our review will answer one of the most important 
questions about the treatment of depression: which 
drug, if any, should be preferred in terms of efficacy, 
tolerability and acceptability during the acute phase 
and the continuation/maintenance treatment phase 
for major depression?
 ► We will use a novel approach to combine the re-
sults of acute-phase treatment network meta-anal-
ysis (NMA) with long-term treatment studies, thus 
enabling the inclusion of all related designs in the 
NMA.
 ► Our primary outcomes, ‘sustained response’ and 
‘all-cause dropouts’,  may have slightly different 
meanings, depending on the study design.
 ► Studies examining some tricyclics for relapse pre-
vention will be excluded from our NMA because our 
focus is on the 21 antidepressants previously includ-
ed in the NMA for the acute treatment of depression.
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as more people live to the age where they can experience 
depressive disorders.3 4 
Pharmacotherapy plays an important role in the 
treatment of depression. At the initiation of treatment, 
both improvement of symptoms in the short term and 
relapse prevention in the long term should be taken 
into account. A comprehensive systematic review of 522 
double-blind randomised controlled trials (RCTs) has 
recently demonstrated that antidepressants are effica-
cious for the acute symptoms of depression and that some 
antidepressants may be more efficacious or more accept-
able than others.5 However, there is insufficient evidence 
regarding long-term treatment. Although antidepres-
sants also reduce relapse rates,6–8 there is no universal 
consensus on how long continuation/maintenance 
treatment should last.9–13 There is also no consensus on 
which antidepressant, if any, should be preferred as a first 
option when envisaging the long-term use.14 The lack of 
evidence raises concerns about the benefits and harms 
of the long-term use of antidepressants.15 It is therefore 
currently difficult to choose an antidepressant in the 
acute phase while taking into account long-term efficacy 
and acceptability.
In this study, we will conduct a pairwise meta-analysis and 
a network meta-analysis (NMA) to examine the relative 
efficacy, tolerability and acceptability of antidepressants 
in the long-term treatment of major depression. First, 
using the pairwise meta-analysis, we will obtain estimates 
of efficacy, tolerability and acceptability of continuing 
antidepressants, in comparison with discontinuing the 
antidepressant after achieving a positive response in the 
acute phase of treatment. Second, using NMA, we will 
estimate the relative efficacy, tolerability and acceptability 
of various antidepressants, in both the acute phase and 
the continuation/maintenance phase of treatments.
MEthOds
We used the Preferred Reporting Items for Systematic 
Reviews and Meta-Analysis Protocols (PRISMA-P).16
Eligibility criteria
Types of studies
We will include double-blind RCTs, in which any of the 21 
antidepressants described further (see the Types of inter-
ventions section) was compared as monotherapy with 
placebo or with another active drug for the long-term 
treatment of unipolar major depression.
We define long-term treatment as the duration of treat-
ment of more than 12 weeks.17 We conceptualise the 
phases of treatment for major depression as consisting 
of the acute-phase treatment lasting up to 3 months, and 
the subsequent continuation/maintenance phase.18 The 
distinction between continuation and maintenance is 
more conceptual than pragmatic,6 and we will include 
both of them in the current analyses.
In the scientific literature, there are four types of meth-
odological designs used to assess the effectiveness of 
drugs used as long-term treatment (figure 1). The most 
commonly used is an ‘enrichment design’.19 In this type 
of study (type A in figure 1), patients who responded to 
an open-label acute treatment (run-in phase) are subse-
quently randomised to continue the active drug or to 
switch to placebo (ie, the randomised sample is enriched 
Figure 1 Different study designs for long-term treatment trials in a major depressive disorder.
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with people who have responded acutely to the active 
agent). The second study design (type B) is a ‘non-enrich-
ment design’, where euthymic patients (ie, in remission) 
are included and randomised (in this type of study, there 
is no run-in or open-label period). The third design (type 
C) is ‘continuation design’, in which patients with acute 
depressive symptoms are randomly allocated to receive 
treatment or placebo (or another active treatment) 
and then followed up for a long-term period (ie, more 
than 3 months). Another type of continuation design is 
the so-called ‘continuation/extension design’ (type D), 
which includes an extension phase, where only partici-
pants who responded to the acute treatment they have 
been allocated to (drug and placebo/another active 
treatment) are followed up in a double-blind fashion. 
Quasi-randomised or cross-over trials will be excluded, 
while cluster RCTs will be included when the clustering 
effect can be taken account of. 
Types of participants
We will include patients aged 18 years or older, of both 
sexes with unipolar major depression diagnosed by 
using any standard operationalised criteria, such as 
Feighner criteria, Research Diagnostic Criteria, Diag-
nostic and Statistical Manual of Mental Disorders (DSM)-III, 
DSM-III-R, DSM-IV, DSM-5 and International Classifica-
tion of Diseases, 10th Revision (ICD-10). Studies in which 
20% or more of the participants suffering from bipolar 
disorder, treatment resistant depression, peripartum 
depression or psychotic depression will be excluded. 
We will include chronic depression (depressive episode 
lasting longer than 2 years) and ‘double depression’ 
(major depression superimposed on dysthymic disorder) 
as long as the patients met the diagnostic criteria of 
major depression at the commencement of acute treat-
ment. We will exclude RCTs that have included patients 
with a concurrent primary diagnosis of another Axis I or 
II disorder. However, a concurrent secondary diagnosis 
of another psychiatric disorder will not be considered as 
exclusion criteria. As depressive symptoms can be influ-
enced by physical illness,20 RCTs focusing on patients with 
a concomitant medical illness will be excluded. We will 
also exclude seasonal affective disorders as their seasonal 
recurrent pattern differs from general depression.21 We 
will include studies that allow the use of rescue medica-
tions, if these medications were made equally available to 
all treatment groups.
Types of interventions
We will include the 21 antidepressants, which showed 
greater efficacy than placebo in the acute treatment of 
major depression in our previous review.5 In this last, all 
antidepressants currently marketed in the USA, Europe 
or Japan were included: agomelatine, bupropion, citalo-
pram, desvenlafaxine, duloxetine, escitalopram, fluox-
etine, fluvoxamine, levomilnacipran, milnacipran, 
mirtazapine, paroxetine, reboxetine, sertraline, venla-
faxine, vilazodone and vortioxetine. In addition to these, 
four drugs were selected: two tricyclic antidepressants 
(amitriptyline and clomipramine) listed in the WHO 
Model List of Essential Medicines, and trazodone and 
nefazodone, as their effect and tolerability profiles differ 
from others.5 We suggest that it is reasonable to focus on 
these 21 antidepressants because, in the long-term treat-
ment of depression, a continuation of the drug to which 
the patient responded in the acute treatment phase is 
recommended. We chose to focus on these 21 antide-
pressants that have evidence of efficacy for acute treat-
ment rather than evaluate a variety of drugs with unclear 
evidence for acute treatment.
We will obtain information about the interventions of 
interest both from head-to-head and placebo controlled 
trials. We will include studies that used the eligible drugs 
as monotherapy for acute treatment in enrichment and 
non-enrichment designs. Studies that used non-pharma-
cological interventions (eg, electroconvulsive therapy and 
psychotherapy) or ineligible drugs for the acute treat-
ment in more than 20% of patients will be excluded.
Outcome measures
Primary outcomes:
 ► Sustained response (efficacy), measured as the propor-
tion of patients who had responded in the acute-
phase treatment and who subsequently did not have 
a depressive relapse during the continuation/mainte-
nance phase, up to the end of the study duration. We 
will use the original authors’ definitions of ‘response’ 
or ‘relapse/recurrence’.
 ► All-cause dropouts (acceptability), measured as the 
proportion of patients who left the trial early due to 
any reason up to the end of the study duration.
Secondary outcomes:
 ► Dropouts due to adverse events (tolerability), measured 
as the proportion of patients who left the trial early, 
either during the acute-phase treatment or during 
the continuation/maintenance treatment, due to any 
adverse events (including specific adverse events and 
withdrawal symptoms).
 ► Occurrence of specific adverse events, as reported in the 
original studies.
 ► Suicidality, measured as the number of patients who 
deliberately self-harmed, attempted or completed 
suicide.
search strategy and data management
Search strategy
We will identify all published, unpublished and ongoing 
RCTs that compared the efficacy and/or acceptability of 
one drug with another or with placebo in the treatment 
of major depression. We will use search terms as follows: 
depress* or dysthymi* or adjustment disorder* or mood 
disorder* or “affective disorder” or “affective symptoms” 
(a full search strategy is in the online supplementary file). 
The following sources will be searched: Cochrane Central 
Register of Controlled Trials, AMED, CINAHL, Embase, 
LILACS database, MEDLINE, MEDLINE In-Progress, 
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PsycINFO and the UK National Research Register. We 
will also hand-search a list of trial databases from drug-ap-
proving agencies (Food and Drug Administration (USA), 
Medicines and Healthcare Products Regulatory Agency 
(UK), European Medicines Agency (Europe), Medicines 
Evaluation Board (the Netherlands), Medical Products 
Agency (Sweden), Pharmaceuticals and Medical Devices 
Agency (Japan) and Therapeutic Goods Administration 
(Australia)) and international trial registries ( clinical-
trials. gov, ISRCTN, National Research Register in the UK, 
the Netherlands Trial Register, EUDRACT, UMIN-CTR, 
JapicCTI and JMACCT, Australian Clinical Trials Registry 
and WHO International Clinical Trials Registry Plat-
form). We will contact the National Institute for Clinical 
Excellence (UK), the Institut für Qualität und Wirtschaft-
lichkeit in Gesundheitswesen (Germany) and representa-
tives of pharmaceutical companies to obtain unpublished 
information (we will also check their websites). No date 
or language restrictions will be applied to any of the 
searches. All relevant authors will be contacted to supple-
ment any unpublished studies or incomplete reporting in 
the original papers and will be reminded twice.
We will include Chinese trials as long as they were regis-
tered in an international database regardless of their 
language. However, we will exclude them when they 
were registered only in a Chinese database. Although 
increasing numbers of clinical trials have been reported 
from mainland China,22 there is a concern about their 
quality.23 24 It has been under debate whether Chinese 
databases should be searched when conducting a system-
atic review.25 Moreover, recent studies have shown that 
the trials indexed in Chinese databases generally suffer 
from numerous quality issues,24 and evaluating their cred-
ibility and integrity is beyond the scope of this work.25 We 
therefore decided to exclude such studies to avoid any 
potential bias that might arise by their inclusion.
Study selection
Two reviewers will independently review references and 
abstracts retrieved by the search. If both reviewers agree 
that a trial does not meet the eligibility criteria, it will be 
excluded. We will obtain the full text of all remaining 
articles and use the same eligibility criteria to determine 
the final selection. Any disagreements will be resolved via 
discussion with a third member of the review team.
Data extraction
Two reviewers will independently extract data and eval-
uate the risk of bias for each selected trial. We will use 
a structured data extraction template designed for this 
study and check the reliability of the data extraction. 
Information extracted will include trial characteris-
tics (eg, lead author, journal, publication year, design, 
blinding and inclusion criteria), participant character-
istics (eg, diagnostic criteria for depression, age range, 
setting and average number of previous episodes), inter-
vention details (eg, duration of treatment, dose ranges 
and mean doses of study drugs) and outcome measures. 
In enrichment trials, we will also extract the details of 
acute treatment before randomisation (ie, length of treat-
ment prior to randomisation and dosage of drug), the 
method of tapering off the active drug after randomisa-
tion in the placebo arm (abrupt or gradual) and the defi-
nition of remission/response required for entry.
Length of trial
We will include any trial with a duration greater than 
3 months. For the main analysis, we will consider the 
longest endpoint data. We will classify studies into several 
groups based on the length of treatment (from the initi-
ation of acute treatment to the end of continuation treat-
ment: >3 and ≤6 months, >6 and ≤12 months, >12 and 
≤24 months, and >24 months) to assess, using subgroup 
analyses, whether the duration of treatment leads to any 
differences in benefit.6
Comparability of dosages
We will include both fixed and flexible dose designs, and 
only include arms randomising patients to drugs within 
the licensed dose range. We will consider all comparisons 
within licensed ranges to be fair comparisons.
Risk of bias assessment
We will assess risk of bias of the included studies with 
regard to the primary outcome, using the tool described 
in the Cochrane Collaboration Handbook as a reference 
guide.26 The assessment will be performed by two inde-
pendent raters. If the raters disagree, the final rating will 
be made by consensus with the involvement of another 
member of the review group. The following domains will 
be assessed: sequence generation, allocation conceal-
ment, blinding of therapists and participants, blinding 
of outcome assessors, incomplete outcome data, selective 
outcome reporting and other source of bias (eg, sponsor-
ship bias). We will contact the authors to obtain missing 
information, if necessary. Overall risk of bias of each study 
will be categorised as follows5 27 : studies will be classified 
as having overall low risk of bias if none of the domains 
above are rated as high risk of bias and three or less are 
rated as unclear risk; and overall moderate if one domain 
is rated as high risk of bias, or none are rated as high 
risk of bias but four or more are rated as unclear risk. 
All other studies will be assumed to pertain to the overall 
high risk of bias group.
statistical analysis
Synthesis of results
We will present the trial and study population charac-
teristics across all eligible trials, describing the types of 
designs, comparisons and important variables, such as 
year of publication, age, sponsorship and clinical setting. 
We will analyse dichotomous outcomes on an inten-
tion-to-treat basis, assuming that all dropouts from the 
treatment had negative outcomes (ie, not sustaining 
response).
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Pairwise meta-analysis
As we aim to answer two clinical questions in this review, 
we will conduct two main analyses. The first clinical ques-
tion relates to whether continuing antidepressants after 
achieving a positive response in the acute-phase treatment 
is beneficial and/or safe. To answer this question, we will 
conduct a pairwise meta-analysis comparing all antide-
pressants (ie, all drugs grouped together) versus placebo 
to investigate the effects of antidepressants in long-term 
treatment (analysis 1). For this analysis, we will only use 
enrichment-design studies (type A in figure 1). We will 
use a random effects meta-analysis model28 to estimate 
odds ratios. We will estimate the heterogeneity parameter 
using restricted maximum likelihood and present the 
95% CIs using the Knapp-Hartung method. In this anal-
ysis, we will consider all primary and secondary outcomes. 
We will use R to perform all analyses.29 Should the event 
be rare for some of the outcomes (eg, zero events in one 
or both treatment arms for some studies), we will consider 
alternative methods for meta-analysis.30
Network meta-analysis
The second clinical question is about how the various 
antidepressants compare with each other, when both the 
acute and the continuation/maintenance phases of the 
treatment are taken into account. For this (analysis 2), 
we will conduct NMAs to examine the comparative effi-
cacy and acceptability of the drugs. NMA is a method 
for jointly synthesising direct and indirect evidence for 
each treatment comparison. It thus allows more studies 
to contribute towards each outcome, for each treatment 
comparison.31 32 However, synthesising the results of the 
four different designs that we expect to find (figure 1) 
via standard NMA methods poses a problem regarding 
transitivity, which is the underpinning assumption of the 
NMA model.33 According to this assumption, there are 
no important differences between studies in clinical and 
methodological aspects that might affect the outcome, 
other than the treatments being compared. In the present 
context, however, we cannot automatically assume that 
participants allocated to different drugs have similar char-
acteristics across the different study designs. For instance, 
participants of an enrichment study will all be responders 
to a particular drug A; participants of another enrichment 
study will all be responders to a different drug (ie, drug 
B). To assume that the patients who acutely responded to 
drug A are identical to those that acutely responded to 
drug B may be wrong. In addition, such an assumption 
(which is equivalent to assuming that drugs A and B are 
equally or similarly effective) defeats the purpose of this 
review, which is to explore possible differences between 
the drugs. Thus, a standard NMA approach including all 
designs will not be appropriate.
To overcome this problem, we will start by performing 
a random effects NMA only using type B and C designs, 
if enough such studies are available (NMA 1). We will 
do this after assuming that treatment effects are similar 
in euthymic patients, and patients with acute depressive 
symptoms. In our analysis, we will assume a common 
heterogeneity variance for all treatment comparisons in 
the network. We will perform this NMA for all primary 
and secondary outcomes.
We anticipate, however, that we can find fewer studies of 
types B and C (enrichment-design studies are much more 
frequent in the scientific literature), possibly employing 
only a subset of the 21 drugs. In this case, NMA one will 
not be able to answer the clinical question at hand. If this 
is the case, we will follow a ‘chain-of-evidence’ approach 
to synthesise the totality of the evidence.34 Using this 
approach, we will amalgamate the results of the NMA of 
acute treatment5 with type A, B, C and D studies to obtain 
an answer to our clinical question.
More concretely, the outcome we are interested in is 
sustained response, which corresponds to ‘long term 
response AND acute response’. Thus, we are interested 
in the probability:
 P
(
long− term response AND acute response, under treatment T) ,
for all different treatments, for the general population of 
patients. Type B, C and D studies inform this outcome 
directly. However, type A studies only give information for 
the outcome ‘long-term response GIVEN acute response’, 
that is, they measure
  P
(
long− term response �� acute response, under treatment T).  
These two probabilities are related via the formula:
 
 
P(long− term response AND acute response, under treatment T)
= P(long− term response | acute response, under treatment T)
×P(acute response, under treatment T)  
 (1)
Thus, in order to allow type A studies (which we expect 
to be the majority of studies) to also inform the quantity of 
interest, that is, the left part of equation (1), we will need 
information about  P
(
acute response, under treatment T
)
 . This probability is not informed by any of the study 
designs in figure 1. We will thus inform this term using 
the results from the existing NMA on acute treatment.5
The steps of our chain-of-evidence analysis plan are as 
follows:
1. We will use the results of the NMA of acute treatment[5] 
to estimate  P
(
acute response, under treatment T
)
  for each 
treatment  T  .
2. We will use type A studies to esti-
mate   P
(
long− term response �� acute response, under treatment T)  for 
each treatment. 
3. We will use the estimates from steps 1 and 2, together with 
equation (1), to estimate for each treatment T  the prob-
ability P
(
long− term response AND acute response, under treatment T) . 
4. We will use results from step 3 to estimate odds ratios 
for all treatments versus an (arbitrarily chosen) control 
treatment.
5. We will use type B, C and D studies to obtain study-spe-
cific estimates for the odds ratios of the corresponding 
treatments, for sustained response.
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6. We will jointly synthesise the estimated effect sizes 
from steps 4 and 5 in another random-effects NMA 
(NMA 2), assuming a common heterogeneity for all 
comparisons in the network. We will report the odds 
ratios for all treatment comparisons, along with their 
corresponding uncertainty.
Note that during steps 1, 2 and 3 of this approach, given 
the information provided by type A studies, we will also be 
able to estimate the effects of composite treatments, for 
example, drug A for the acute phase and placebo for the 
continuation. We will perform this analysis for the first 
primary outcome only, sustained response. All analyses 
will be performed in R.
Assessment of heterogeneity (pairwise meta-analysis)
In the pairwise meta-analysis, we will check the possibility 
of heterogeneity by visually inspecting the forest plots. We 
will then report the estimated value for the heterogeneity 
variance and compare it with the corresponding empir-
ical distribution.35 36 Finally, we will report the I2 statistic,37 
which corresponds to the percentage of the variability 
due to heterogeneity rather than a sampling error. In the 
NMA, we will estimate the heterogeneity variance and 
judge its magnitude by comparing it with empirical distri-
butions.35 36
Assessment of the transitivity assumption (NMA)
As discussed previously, transitivity is a fundamental 
assumption for NMA. The distribution of potential 
effect modifiers should be balanced across treatment 
comparisons.
For NMA 1, we will check for significant differences in 
the distribution of the following factors among different 
comparisons: severity of depression before randomisa-
tion, age, average number of previous episodes and clin-
ical setting.
Checking transitivity for NMA 2 will require one addi-
tional step, namely, we will check whether important 
effect modifiers have similar distributions between the 
studies included in the NMA for acute treatment5 and the 
enrichment studies (type A) before enrichment. This is 
needed to ensure that step 3 of the analysis is valid, that 
is, that the different terms of equation (1) are estimated 
in similar populations. Also, we will check whether the 
participants’ characteristics and severity of depression 
are similar enough between the studies included in acute 
NMA and those with continuation designs (ie, type C and 
D).
Assessment of inconsistency
Another method for assessing the validity of a NMA is 
to check whether the network is consistent, that is, that 
there is statistical agreement between direct and indirect 
evidence on the same comparisons. Consistency is a reflec-
tion of the transitivity of the NMA, and a breach in the 
transitivity assumption may lead to important inconsisten-
cies in the network.32 In NMA 1, we will evaluate the consis-
tency by using two approaches: via the back-calculation 
method to assess local inconsistency,38 and the design-
by-treatment test to assess the global inconsistency in the 
network.39 In case we identify important inconsistency, we 
will explore possible sources via subgroup and metare-
gression analyses (described further). If the extent of 
inconsistency is deemed important, we will abstain from 
performing any further analyses. In addition, this anal-
ysis assumes that treatment effects are similar in euthymic 
patients and in patients with acute depressive symptoms. 
We will explore the plausibility of this assumption by 
checking whether the estimated treatment effects in type 
B and C studies are in statistical agreement.
In NMA 2, we will assess inconsistency in step 6 by 
checking for differences between the estimates obtained 
using type A studies in conjunction with the NMA of acute 
treatment5 versus the estimates obtained from type B, C 
and D studies.
Assessment of publication bias and small study effect
In order to assess whether small studies report higher 
effect estimates than larger studies (due to publication 
bias/small study effect) in the pairwise meta-analysis, we 
will visually examine the contour-enhanced funnel plots 
and perform the Peters test.40 For NMA 1, we will use 
comparison-adjusted funnel plots, after assuming that 
newer treatments are favoured.41
We will also evaluate the influence of publication 
bias by performing subgroup analyses of published 
versus unpublished data.
sensitivity analyses and subgroup analyses
In order to investigate possible heterogeneity in the 
pairwise meta-analysis, we will examine the effect of the 
following study-level characteristics, in metaregressions 
or subgroup analyses: (1) study year, (2) length of acute 
treatment at the time of randomisation, (3) length of 
remission required before randomisation, (4) average 
age of patients, (5) average number of previous episodes, 
(6) clinical setting and (7) type of discontinuation of the 
antidepressant.
For NMA 2, we will conduct a subgroup analysis after 
grouping trials (if possible) according to their dura-
tions (>3 and ≤6 months, >6 and ≤12 months, >12 and 
≤24 months, and >24 and ≤36 months). If possible (ie, 
depending on the data we will obtain), we will instead 
perform a multiple-outcome NMA to jointly synthesise 
treatment effect estimates at multiple time points.42 43 
We will also perform an analysis aiming to assess novelty 
effects.44
Finally, depending on data availability, we will exclude 
continuation non-extension design (ie, type C studies) 
because they possibly included people who have not 
responded after the acute treatment phase, and they 
would have been excluded in enrichment and continua-
tion–extension design.
Depending on other data that might become available, 
we will perform further post hoc analyses to assess the 
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influence of additional factors possibly related to treat-
ment effects.
GrAdE quality assessment
The risk of bias of individual trials and the certainty of 
evidence contributing to network estimates of the primary 
outcomes will be assessed by Confidence in Network 
Meta-Analysis (Software) (CiNEMA) using the Grading of 
Recommendations Assessment, Development and Evalu-
ation (GRADE) framework45 for NMA 1. The full article 
will be reported following standardised guidelines.46
Patient and public involvement
There was no patient and public involvement in the 
design of this study.
dIsCussIOn
This review aims to provide the best evidence summary 
about the long-term treatment of major depression. By 
extending the current evidence regarding acute treat-
ment, the findings of this review will hopefully give us a 
better understanding of the relative efficacy, acceptability 
and tolerability of antidepressants while taking into 
account both the acute and long-term treatments.
We will address two related clinical questions regarding 
continuation/maintenance treatment for major depres-
sion. Once remitted from the acute phase of antidepres-
sant therapy, should one continue the antidepressant? 
If yes, in view of such long-term treatment, which anti-
depressants, if any, would be preferred at the time of 
the initiation of the acute-phase treatment? Although 
previous systematic reviews of long-term treatment of 
antidepressants showed the efficacy of continuation 
treatment, they focused on a particular design6 7 19 47 or 
analysed various designs together without accounting 
for their differences.8 Moreover, the relative efficacy of 
various drugs has never been studied.
However, synthesis of studies of the long-term treat-
ment of major depression using different designs into 
the NMA framework poses a number of challenges. For 
example, there are two issues in pooling enrichment-de-
sign studies examining different drugs in the NMA. First, 
patients who have responded to drug A and have then 
been randomised to continue drug A or switch to placebo 
may be different in known and/or unknown characteris-
tics from those who have responded to drug B and then 
randomised to B or placebo, that is, there is an issue 
regarding the joint randomisability of such patients,32 48 
which might render the transitivity assumption invalid. 
Second, even if we could somehow overcome the tran-
sitivity issue, the enrichment studies would only form a 
so-called ‘star network’, with the placebo being the only 
common comparator, that is, there will be no closed 
loops in the network, and all the comparisons among the 
active drugs will be indirect and hence will probably give 
imprecise estimates. Pooling together enrichment-de-
sign studies and continuation-design studies with or 
without extension, would close the network but would 
pose yet another issue; the former will have randomised 
euthymic patients, while the latter will have randomised 
acutely symptomatic patients who responded to specific 
drugs, again posing threats to the joint randomisability 
assumption.
To overcome these issues, we will use a novel approach 
that will combine the results of acute-phase treatment 
NMA5 with the enrichment-design studies, and then 
further pool them with studies of the other designs. 
However, this new methodology has its own weaknesses. 
First, our new approach of combining the results of the 
NMA of acute treatment and those of enrichment-design 
trials does not preserve randomisation among the arms 
because we will compare groups that were not originally 
randomised into the arms. We will use the probability 
of response in the previous NMA of acute treatment 
and combine it with evidence from enrichment-design 
studies to obtain the probability of sustaining response/
remaining in treatment in long-term treatment. We 
propose this new approach because it will enable us to 
use all related designs to answer the clinically relevant 
questions. Second, we chose ‘sustained response’ and 
‘all-cause dropouts’ as our primary outcomes because 
they are clinically important and are expected to be 
reported across various designs. However, these outcomes 
may have slightly different meanings, depending on 
the design. In the enrichment design, the ‘sustaining 
response’ group will include participants who have 
responded to the acute treatment and remain free of 
relapse up to the end of continuation treatment, while in 
continuation design, the sustained response group may 
include participants who met the criteria of response 
at the end of study. We will describe these differences, 
if there are any, and discuss their impact on the review 
findings. Finally, we decided to focus on the 21 antide-
pressants that we included in the previous NMA for the 
acute treatment of depression.5 We are aware that several 
studies examining tricyclics (eg, nortriptyline and imip-
ramine) for relapse prevention will then be excluded 
from our NMA. This will not, however, undermine the 
clinical importance of our study because tricyclics and 
the older antidepressants are not recommended as first-
line treatment for depression.
Notwithstanding these weaknesses, our review will 
summarise the best available evidence to answer one of 
the most important questions about the treatment for 
depression: which drug, if any, should be preferred in 
view of efficacy, tolerability and acceptability of the agents 
through the acute-phase and continuation/maintenance 
treatments for major depression? We believe that the 
results of our NMA will help clinicians and patients make 
better-informed choices from a long-term perspective, 
when they initiate antidepressant treatments for their 
acute depressive symptoms.
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